Cas:108284-85-1 2,2-dimethyl-5-propan-2-yl-5H-1,3-thiazole manufacturer & supplier

Chemical Name:2,2-dimethyl-5-propan-2-yl-5H-1,3-thiazole

CAS.NO:108284-85-1

Synonyms:rac-2,2-dimethyl-5-isopropyl-2,5-dihydro-1,3-thiazole;3-Thiazoline,2,2-dimethyl-5-isopropyl;Thiazole,2,5-dihydro-2,2-dimethyl-5-(1-methylethyl);2,2-Dimethyl-5-isopropyl-3-thiazoline

Molecular Formula:C₈H₁₅NS

Molecular Weight:157.27600

HS Code:2934100090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:229.8ºC at 760mmHg

Density:1.02g/cm3

Index of Refraction:1.53

PSA:37.66000

Exact Mass:157.09300

LogP:2.00030

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like rac-2,2-dimethyl-5-isopropyl-2,5-dihydro-1,3-thiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2-Dimethyl-5-isopropyl-3-thiazoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2-Dimethyl-5-isopropyl-3-thiazoline Use and application,2,2-Dimethyl-5-isopropyl-3-thiazoline technical grade,usp/ep/jp grade.

Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. 2,2-dimethyl-5-propan-2-yl-5H-1,3-thiazole manufacturer In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better. 2,2-dimethyl-5-propan-2-yl-5H-1,3-thiazole supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 2,2-dimethyl-5-propan-2-yl-5H-1,3-thiazole vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2,2-dimethyl-5-propan-2-yl-5H-1,3-thiazole factory Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days.